Alerts will be sent to your verified email
Verify EmailPARMAX
Parmax Pharma
|
Emmessar Biotech&Nut
|
Venmax Drugs&Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Financials
|
|||
5 yr Average ROE
|
-1624.87 % | 13.7 % | -44.32 % |
5yr average Equity Multiplier
|
46.04 | 1.24 | -0.19 |
5yr Average Asset Turnover Ratio
|
0.95 | 0.36 | 0.32 |
5yr Avg Net Profit Margin
|
-9.48 % | 71.53 % | -30.94 % |
Price to Book
|
0.0 | 1.82 | 3.42 |
P/E
|
0.0 | 34.72 | 0.0 |
5yr Avg Cash Conversion Cycle
|
-161.05 Days | 68.18 Days | 0.0 |
Inventory Days
|
73.65 Days | 62.21 Days | 24.83 Days |
Days Receivable
|
40.27 Days | 10.88 Days | 0.0 |
Days Payable
|
328.05 Days | 199.95 Days | 189.56 Days |
5yr Average Interest Coverage Ratio
|
1.16 | 815.2 | -318.36 |
5yr Avg ROCE
|
-9.94 % | 19.97 % | -45.33 % |
5yr Avg Operating Profit Margin
|
3.93 % | -101.39 % | -50.41 % |
5 yr average Debt to Equity
|
17.42 | 0.0 | -0.64 |
5yr CAGR Net Profit
|
n/a | 0.0 | n/a |
5yr Average Return on Assets
|
-6.43 % | 10.86 % | 187.49 % |
Shareholdings
|
|||
Promoter Holding
|
30.8 % | 59.53 % | 23.13 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.0 | 1.34 % | 0.0 |
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
Parmax Pharma
|
Emmessar Biotech&Nut
|
Venmax Drugs&Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|